Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sankyo Pharma Gmbh
Age
35–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Mean sitting sBP and dBP prior to randomization of 140-180/90-105 mmHg
Increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral atherosclerotic disease stage IIa or lower; b) diabetes mellitus type 2; c) left ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction, stroke or TIA
Intima-media thickness of the common carotid artery greater than or equal to 0.8 and less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl
You may not be if
Body mass index \> 30
Any type of known secondary hypertension
Electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (\< 50/min)
Obstructive pulmonary disease
Claudicatio intermittens
History or clinical evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial
Hypersensitivity or contraindication to ARBs, Beta-Blockers, HCTZ or any cross allergy
Pre-treatment with ARBs or ACE inhibitors within 6 months prior to screening
Treatment with disallowed medication
Pregnant or breastfeeding females or females of childbearing potential without adequate contraception